SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1628165
This article is part of the Research TopicAdvancement of Chemotherapy in Breast Cancer: Predictive Markers, Resistance Mechanism and Therapeutic StrategiesView all 7 articles
A Systematic Review of Progress toward Unlocking the Power of Epigenetics in Breast Cancer: Latest Updates and Perspectives
Provisionally accepted
- Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi, Saudi Arabia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Breast cancer (BC) is among the most prevalent malignancies globally. It is progressively acknowledged as a diverse type of cancer, exhibiting considerable differences in its genomic and transcriptomic characteristics. Its growing evidence highlights the substantial role of epigenetic modification in pathogenesis, prognosis and treatment. Cancer and epigenetics are closely linked; abnormal epigenetic changes can influence numerous aspects of cancer biology, including unusual transcription patterns, initiation of cancer, its progression, resistance to drugs, and metastasis. Epigenetic drugs (epi-drugs), including DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, serve as promising therapeutic agents, particularly in combination with conventional therapies. Additionally, nanotechnology-assisted epi-drug delivery systems are emerging as innovative approaches to enhance treatment efficacy and reduce systemic toxicity. While several epigenetic biomarkers have shown potential in liquid and tissue biopsies, their clinical validation remains a challenge. The integration of epigenetic insights into personalized medicine could revolutionize BC management, offering more targeted and effective treatment strategies. This systematic review aims to evaluate recent advancement in epigenetic research related to BC, focusing on diagnostic and prognostic biomarkers, epigenetic-based therapies and ongoing clinical trials. A comprehensive literature search was carried out in databases like PubMed, Scopus, and Google Scholar up to January 2025, following PRISMA guidelines. Seventy two (72) studies were included, addressing key aspects of DNA methylation, histone modification, and non-coding RNAs as potential biomarkers for early detection and disease progression monitoring.
Keywords: breast cancer, epigenetics, biomarkers, personalized medicine, Nanotechnology
Received: 13 May 2025; Accepted: 29 Aug 2025.
Copyright: © 2025 Alotaibi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ghallab Alotaibi, Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.